We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PharmaNet Announces Observational Research Survey Results

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The survey is designed to enhance the understanding of observational research among sponsors, regulators, policymakers, physicians and patients.

“Observational research is an important vehicle for compiling post-approval data on real world clinical performance, economic value, patient quality of life and product safety,” commented Jeff Trotter, Executive Vice President, Phase IV Development, and principal author of the survey.

Mr. Trotter continued, “Observational studies are different from pre-approval clinical trials. The survey results reinforce our experience assisting clients in understanding, planning, designing and executing these increasingly critical studies in a cost-efficient manner.”

To date, nearly 1000 industry professionals from over twenty-five countries have participated in the four surveys.  A report on the survey is available with sections on organizational responsibility, terminology, strategic rationale, methodology, operational processes and future considerations.